CompletedNCT05086250
Oral ketamine or placebo for anxiety during pancreatic cancer care
About this title
Read the official source — NCT05086250Medication studyAges 18+United States
Understand this study
Who was this study for?
This study was for people with anxiety. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Los AngelesSee all locations and recruitment
- Study phase
- Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
Study information
Study start dateStarted: October 20, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 12
- Sponsor
- Cedars-Sinai Medical Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Early Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT05086250
- Official title
Show the full official title
A Prospective, Single Center, Double Blind, Randomized, Crossover Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Los Angeles
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Cedars-Sinai Medical Center, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including ketamine and Placebo.
Who was this study for?
This study was for people with anxiety. Listed age limits: from 18 years. Other eligibility criteria applied.
